4.2 Article

Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase

Journal

KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
Volume 14, Issue 5, Pages 299-304

Publisher

KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
DOI: 10.4196/kjpp.2010.14.5.299

Keywords

AMP-activated protein kinase (AMPK); Angiotensin II type 1 (AT(1)) receptor antagonist; Losartan; Vascular smooth muscle cells (VSMCs); Proliferation

Funding

  1. Korea Science and Engineering Foundation (KOSEF) through the Aging associated Vascular Disease Research Center at Yeungnam University [2010 0007386]
  2. National Research Foundation of Korea [2010-0007386] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Losartan is a selective angiotensin II (Ang II) type 1 (AT(1)) receptor antagonist which inhibits vascular smooth muscle cells (VSMCs) contraction and proliferation We hypothesized that losartan may prevent cell proliferation by activating AMP-activated protein kinase (AMPK) in VSMCs VSMCs were treated with various concentrations of losartan AMPK activation was measured by Western blot analysis and cell proliferation was measured by MTT assay and flowcytometry Losartan dose- and time-dependently increased the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase (ACC) in VSMCs Losartan also significantly decreased the Ang II- or 15% FBS-induced VSMC proliferation by inhibiting the expression of cell cycle associated proteins, such as p-Rb, cyclin D, and cyclin E Compound C, a specific inhibitor of AMPK, or AMPK siRNA blocked the losartan-induced inhibition of cell proliferation and the G(0)/G(1) cell cycle arrest These data suggest that losartan-induced AMPK activation might attenuate Ang II-induced VSMC proliferation through the inhibition of cell cycle progression

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available